How Strong Is the Mushroom? Oregon Decides It Has to Know

Every administration session in Oregon starts with a consent conversation, and somewhere in that conversation the client asks what the dose will feel like. You can describe ranges. You can describe past sessions. What you cannot honestly promise is that this 25 milligrams will behave like the last 25 milligrams, because right now the answer depends partly on the product's chemistry and the lab that tested it. Informed consent for an experience of unpredictable intensity is consent with an asterisk on it.

That asterisk is what the Oregon Health Authority's 2026 Product Potency Workgroup exists to shrink. Oregon psilocybin potency sounds like a regulatory niche topic. It's actually a safety variable that sits inside every dosing decision a facilitator makes.

Oregon Psilocybin Services convened its Product Potency Workgroup on March 3, 2026, bringing together every licensed manufacturer and laboratory in the program, the Oregon Environmental Laboratory Accreditation Program (ORELAP), and members of the public. The agenda: potency formulas, including a "total psilocybin equivalent" approach, and safety concerns about high-psilocin products being used in lower-dose sessions.

A few things worth being precise about. This was a workgroup, not rulemaking; OPS says its findings "may inform" rulemaking later in 2026, and nothing has changed in the rules yet. There was one meeting, and OPS decided a second wasn't needed. Members were asked to keep submitting peer-reviewed research on psilocin-to-psilocybin ratios and on what thresholds keep a dose genuinely subperceptual. In other words: the state has identified the problem, gathered the people who measure it, and is still deciding what to do about it.

Psilocybin is a prodrug. The body converts it to psilocin, which is the compound doing the receptor-level work. Oregon's lab rules already require both values to be reported separately, plus a calculated figure called Total Potential Psilocin: the psilocin already present, plus 0.719 times the psilocybin content, an estimate of the full active dose available after conversion (OAR 333-064-0150).

But the program's session requirements, including the duration tiers and quantity limits, are keyed to milligrams of psilocybin analyte. That gap matters. Two products labeled with the same psilocybin number can carry meaningfully different amounts of preformed psilocin, and the one with more psilocin doesn't need to wait for conversion. Faster onset, steeper intensity curve, same number on the label.

For facilitators this isn't abstract chemistry. Onset timing shapes when a client needs you closest. Intensity shapes whether the preparation you did together matches the experience they get. And dose predictability is the foundation under both.

The workgroup's framing pointed at a specific scenario: high-psilocin products used for lower-dose sessions. A client seeking a subperceptual or mild experience is the client with the least tolerance for surprise; they chose that dose because they did not consent to more. If the product's preformed psilocin pushes a nominally light dose into clearly perceptual territory, the mismatch between what the client agreed to and what they received is a consent problem wearing a chemistry costume.

There's a structural observation here too, stated as observation: in a market where service centers are closing and margins are thin, product differentiation is one of the few competitive levers manufacturers have. Novel high-psilocin products aren't a conspiracy. They're what markets produce. Which is exactly why the measurement standards can't be left to the market to sort out.

Three practical points while the rulemaking question stays open:

• Read the full certificate of analysis, not just the headline number. Psilocin and psilocybin values are reported separately. The ratio between them tells you more about onset and intensity than either number alone.
• Build the ratio into preparation and consent conversations. "This product has more preformed psilocin, so it may come on faster" is a sentence a client can actually use.
• Watch OPS rulemaking through the rest of 2026. If "total psilocybin equivalent" or a similar formula moves from workgroup discussion into rule, dosing tiers, labels, and your consent paperwork could all shift with it.

The deeper point is one facilitators already know from practice: set and setting get the attention, but the substance is a variable too, and it's the one we've been measuring least consistently. A state deciding it has to know how strong the mushroom is, precisely and comparably across products, is the system catching up to what good clinical judgment already required.

Dosing conversations, preparation, and consent are clinical skills, and they're the ones this rulemaking will touch first. The OPS Facilitator Clinical Skills CE Bundle covers the facilitation competencies that don't change when the formulas do.

Psilocybin is a prodrug the body converts to psilocin, the active compound. Oregon's session rules are keyed to psilocybin milligrams, but two products with the same psilocybin number can carry different amounts of preformed psilocin, producing faster onset and steeper intensity. That gap makes dose less predictable than the label suggests, which is a consent and safety concern.

Oregon Psilocybin Services convened the workgroup on March 3, 2026, with every licensed manufacturer and lab, the state accreditation program, and the public. It examined potency formulas, including a "total psilocybin equivalent" approach, and safety concerns about high-psilocin products in lower-dose sessions. It was one meeting that may inform later rulemaking; no rule has changed yet.

Total Potential Psilocin is a calculated figure Oregon labs must report: the psilocin already present plus 0.719 times the psilocybin content, estimating the full active dose available after the body converts psilocybin to psilocin. Reading it alongside the separate psilocin and psilocybin values on the certificate of analysis tells facilitators more about onset and intensity than any single number.

Read the full certificate of analysis, not just the headline psilocybin number, and note the psilocin-to-psilocybin ratio, which shapes onset and intensity. Build that into preparation and consent: "this product has more preformed psilocin, so it may come on faster." Watch OPS rulemaking through 2026, since dosing tiers, labels, and consent paperwork could shift with it.